LRMR
NASDAQ · Biotechnology
Larimar Therapeutics Inc
$3.21
+0.14 (+4.39%)
Open$3.07
Previous Close$3.08
Day High$3.24
Day Low$3.03
52W High$6.42
52W Low$2.72
Volume—
Avg Volume1.66M
Market Cap319.44M
P/E Ratio—
EPS$-1.99
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+624.9% upside
Current
$3.21
$3.21
Target
$23.27
$23.27
$16.60
$23.27 avg
$30.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 175.11M | 171.92M | 184.32M |
| Net Income | -19,494,630 | -18,016,562 | -21,970,966 |
| Profit Margin | -11.1% | -10.5% | -11.9% |
| EBITDA | -28,814,403 | -28,168,357 | -29,490,113 |
| Free Cash Flow | -20,989,250 | -18,411,143 | -19,560,158 |
| Rev Growth | -5.1% | +17.2% | +14.9% |
| Debt/Equity | 0.69 | 0.58 | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |